Journal of Shanghai Jiao Tong University (Medical Science) ›› 2024, Vol. 44 ›› Issue (3): 385-392.doi: 10.3969/j.issn.1674-8115.2024.03.012
• Review • Previous Articles
BAI Wenhui1(), SHEN Shukun2, WU Yingli1()
Received:
2023-07-26
Accepted:
2024-01-02
Online:
2024-03-28
Published:
2024-04-29
Contact:
WU Yingli
E-mail:baiwenhui@sjtu.edu.cn;wuyingli@shsmu.edu.cn
Supported by:
CLC Number:
BAI Wenhui, SHEN Shukun, WU Yingli. Research progress in the anti-cancer activity and related mechanisms of arenobufagin[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(3): 385-392.
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2024.03.012
Type of tumor | Type of cell | IC50 |
---|---|---|
Pancreatic cancer | Panc-1 | 10 nmol/L[ |
AsPC-1 | 1 nmol/L[ | |
SW 1990 | 9.9 nmol/L[ | |
BxPC-3 | 48.72 nmol/L[ | |
Lung cancer | A549 | 10 nmol/L[ |
Breast cancer | MCF 7 | 485 nmol/L[ |
Esophageal carcinoma | Eca-109 | 0.8 μmol/L[ |
TE-11 | 3.6 μmol/L[ | |
Glioma | U-87 MG | 10.3 nmol/L[ |
Cervical cancer | HELA | 23 nmol/L[ |
Colon cancer | HT-29 | 25 nmol/L[ |
Tab 1 IC50 of different cells treated with ARE for 24 h
Type of tumor | Type of cell | IC50 |
---|---|---|
Pancreatic cancer | Panc-1 | 10 nmol/L[ |
AsPC-1 | 1 nmol/L[ | |
SW 1990 | 9.9 nmol/L[ | |
BxPC-3 | 48.72 nmol/L[ | |
Lung cancer | A549 | 10 nmol/L[ |
Breast cancer | MCF 7 | 485 nmol/L[ |
Esophageal carcinoma | Eca-109 | 0.8 μmol/L[ |
TE-11 | 3.6 μmol/L[ | |
Glioma | U-87 MG | 10.3 nmol/L[ |
Cervical cancer | HELA | 23 nmol/L[ |
Colon cancer | HT-29 | 25 nmol/L[ |
Type of tumor | Type of cell | Up-regulation | Down-regulation |
---|---|---|---|
Pancreatic cancer, lung cancer, breast cancer, esophageal squamous cell carcinoma, osteosarcoma[ | BxPC-3, SW 1900, A549, NCI-H460, MCF 7, Eca-109 | Cleaved CASPASE 9 | |
Pancreatic cancer, lung cancer[ | BxPC-3, SW 1900, A549, NCI-H460 | Cleaved CASPASE 3 | |
Pancreatic cancer, lung cancer, liver cancer, breast cancer[ | BxPC-3, SW 1900, A549, NCI-H460, HepG2/ADM, MCF 7 | Cleaved PARP | |
Esophageal squamous cell carcinoma[ | Eca-109 | Cleaved CASPASE 8 | |
Breast cancer[ | MCF 7, MDA-MB-468 | NOXA | |
Breast cancer, esophageal squamous cell carcinoma, pancreatic cancer[ | MCF 7, MDA-MB-468, Eca-109, SW 1990, BxPC-3 | P53 | |
Liver cancer, breast cancer, lung cancer, acute leukemia[ | HepG2/ADM, MCF 7, A549, Jurkat, MV-4-11, PC-9 | BAX | |
Breast cancer[ | MCF 7 | P-JNK | |
Acute leukemia[ | Jurkat, MV-4-11 | AIF | |
Liver cancer[ | HepG2/ADM | LC3Ⅱ | |
Breast cancer[ | HELA | ROS | |
Pancreatic cancer[ | SW 1990, BxPC-3 | SMAD3 | |
Pancreatic cancer, breast cancer, lung cancer[ | Panc-1, AsPC-1, PC-9 | P-ERK | |
Pancreatic cancer, breast cancer[ | Panc-1, AsPC-1 | P-AKT | |
Breast cancer[ | MCF 7, MDA-MB-48 | MCL-1 | |
Lung cancer[ | PC-9 | P-MEK | |
Liver cancer, lung cancer[ | HepG2/ADM, A549, PC-9 | BCL-2 | |
Pancreatic cancer[ | SW 1990, BxPC-3 | PI3K | |
Lung cancer[ | PC-9 | C-RAF | |
Pancreatic cancer[ | SW 1990, BxPC-3 | mTOR | |
Liver cancer[ | HepG2 | STAT3 | |
Acute leukemia[ | Jurkat, MV-4-11 | XIAP | |
Liver cancer[ | HepG2/ADM | LC3Ⅰ | |
Lung cancer[ | A549 | SOD | |
Lung cancer[ | A549 | GSH | |
Pancreatic cancer[ | SW 1990, BxPC-3 | AMPK | |
Pancreatic cancer[ | SW 1990, BxPC-3 | P62 |
Tab 2 Proteins related to apoptosis and autophagy induced by ARE
Type of tumor | Type of cell | Up-regulation | Down-regulation |
---|---|---|---|
Pancreatic cancer, lung cancer, breast cancer, esophageal squamous cell carcinoma, osteosarcoma[ | BxPC-3, SW 1900, A549, NCI-H460, MCF 7, Eca-109 | Cleaved CASPASE 9 | |
Pancreatic cancer, lung cancer[ | BxPC-3, SW 1900, A549, NCI-H460 | Cleaved CASPASE 3 | |
Pancreatic cancer, lung cancer, liver cancer, breast cancer[ | BxPC-3, SW 1900, A549, NCI-H460, HepG2/ADM, MCF 7 | Cleaved PARP | |
Esophageal squamous cell carcinoma[ | Eca-109 | Cleaved CASPASE 8 | |
Breast cancer[ | MCF 7, MDA-MB-468 | NOXA | |
Breast cancer, esophageal squamous cell carcinoma, pancreatic cancer[ | MCF 7, MDA-MB-468, Eca-109, SW 1990, BxPC-3 | P53 | |
Liver cancer, breast cancer, lung cancer, acute leukemia[ | HepG2/ADM, MCF 7, A549, Jurkat, MV-4-11, PC-9 | BAX | |
Breast cancer[ | MCF 7 | P-JNK | |
Acute leukemia[ | Jurkat, MV-4-11 | AIF | |
Liver cancer[ | HepG2/ADM | LC3Ⅱ | |
Breast cancer[ | HELA | ROS | |
Pancreatic cancer[ | SW 1990, BxPC-3 | SMAD3 | |
Pancreatic cancer, breast cancer, lung cancer[ | Panc-1, AsPC-1, PC-9 | P-ERK | |
Pancreatic cancer, breast cancer[ | Panc-1, AsPC-1 | P-AKT | |
Breast cancer[ | MCF 7, MDA-MB-48 | MCL-1 | |
Lung cancer[ | PC-9 | P-MEK | |
Liver cancer, lung cancer[ | HepG2/ADM, A549, PC-9 | BCL-2 | |
Pancreatic cancer[ | SW 1990, BxPC-3 | PI3K | |
Lung cancer[ | PC-9 | C-RAF | |
Pancreatic cancer[ | SW 1990, BxPC-3 | mTOR | |
Liver cancer[ | HepG2 | STAT3 | |
Acute leukemia[ | Jurkat, MV-4-11 | XIAP | |
Liver cancer[ | HepG2/ADM | LC3Ⅰ | |
Lung cancer[ | A549 | SOD | |
Lung cancer[ | A549 | GSH | |
Pancreatic cancer[ | SW 1990, BxPC-3 | AMPK | |
Pancreatic cancer[ | SW 1990, BxPC-3 | P62 |
1 | 姜珊, 谢明, 郑佳, 等. 蟾蜍类药材本草考证[J]. 亚太传统医药, 2020, 16(12): 95-99. |
JIANG S, XIE M, ZHENG J, et al. Textual research on toad medicinal materials[J]. Asia-Pacific Traditional Medicine, 2020, 16(12): 95-99. | |
2 | 刘京京, 王静宜, 郭夫江, 等. 中药蟾酥化学成分研究[J]. 中药材, 2021, 44(10): 2321-2325. |
LIU J J, WANG J Y, GUO F J, et al. Chemical constituents of bufonis venenum[J]. Journal of Chinese Medicinal Materials, 2021, 44(10): 2321-2325. | |
3 | TIAN H Y, WANG L, ZHANG X Q, et al. Bufogargarizins A and B: two novel 19-norbufadienolides with unprecedented skeletons from the venom of Bufo bufo gargarizans[J]. Chemistry, 2010, 16(36): 10989-10993. |
4 | LI F J, HU J H, REN X, et al. Toad venom: a comprehensive review of chemical constituents, anticancer activities, and mechanisms[J]. Arch Pharm, 2021, 354(7): e2100060. |
5 | WEI X L, YANG J, MAO Y Q, et al. Arenobufagin inhibits the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway and induces apoptosis and autophagy in pancreatic cancer cells[J]. Pancreas, 2020, 49(2): 261-272. |
6 | ZHANG D M, LIU J S, DENG L J, et al. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway[J]. Carcinogenesis, 2013, 34(6): 1331-1342. |
7 | DENG L J, LEI Y H, QUAN J Y, et al. 1β-OH-arenobufagin induces mitochondrial apoptosis in hepatocellular carcinoma through the suppression of mTOR signaling pathway[J]. J Ethnopharmacol, 2021, 266: 113443. |
8 | LV J H, LIN S H, PENG P L, et al. Arenobufagin activates p53 to trigger esophageal squamous cell carcinoma cell apoptosis in vitro and in vivo[J]. Onco Targets Ther, 2017, 10: 1261-1267. |
9 | YUAN B, HE J, KISOH K, et al. Effects of active bufadienolide compounds on human cancer cells and CD4+CD25+Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells[J]. Oncol Rep, 2016, 36(3): 1377-1384. |
10 | DONG Q, TURDU G, DONGMULATI N, et al. Bufadienolides from the Bufo viridis toad venom exert cytotoxic effects on cancer cells by inducing cell apoptosis and cell cycle arrest[J]. Toxicol In Vitro, 2023, 89: 105566. |
11 | WANG T J, ZHUANG Z M, ZHANG P, et al. Effect of arenobufagin on human pancreatic carcinoma cells[J]. Oncol Lett, 2017, 14(4): 4971-4976. |
12 | 高波, 魏晓露, 韩玲玉, 等. 华蟾素注射液中酯蟾毒配基的分离及体内外抗肿瘤活性筛选[J]. 中国实验方剂学杂志, 2017, 23(16): 78-84. |
GAO B, WEI X L, HAN L Y, et al. Research on isolation of bufadienolides from cinobufacin injection and its activity screening of anti-cancer in vivo and in vitro[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2017, 23(16): 78-84. | |
13 | KAN J, HUANG H F, JIANG Z Y, et al. Arenobufagin promoted oxidative stress-associated mitochondrial pathway apoptosis in A549 non-small-cell lung cancer cell line[J]. Evid Based Complement Alternat Med, 2020, 2020: 8909171. |
14 | ZHAO L J, ZHAO H Y, WEI X L, et al. The lipid homeostasis regulation study of arenobufagin in zebrafish HepG2 xenograft model and HepG2 cells using integrated lipidomics-proteomics approach[J]. J Ethnopharmacol, 2020, 260: 112943. |
15 | DENG L J, QI M, PENG Q L, et al. Arenobufagin induces MCF-7 cell apoptosis by promoting JNK-mediated multisite phosphorylation of Yes-associated protein[J]. Cancer Cell Int, 2018, 18: 209. |
16 | MA L, ZHU Y D, FANG S, et al. Arenobufagin induces apoptotic cell death in human non-small-cell lung cancer cells via the Noxa-related pathway[J]. Molecules, 2017, 22(9): 1525. |
17 | ZHANG Y, YUAN B, BIAN B L, et al. Cytotoxic effects of hellebrigenin and arenobufagin against human breast cancer cells[J]. Front Oncol, 2021, 11: 711220. |
18 | 李志强, 姜秀星, 胡金娇, 等. 沙蟾毒精激活Rho A/ROCK1信号通路诱导急性白血病细胞凋亡的分子机制研究[J]. 陆军军医大学学报, 2022, 44(7): 700-710. |
LI Z Q, JIANG X X, HU J J, et al. Arenobufagin induces apoptosis in acute leukemia cells by activating Rho a/ROCK1 signaling pathway[J]. Journal of Army Medical University, 2022, 44(7): 700-710. | |
19 | 刘倩, 胡春萍, 曹鹏, 等. 沙蟾毒精诱导肺癌PC-9细胞的凋亡效应及其作用机制初探[J]. 天然产物研究与开发, 2017, 29(12): 2030-2035. |
LIU Q, HU C P, CAO P, et al. The effects and mechanisms of apoptosis induced by arenobufagin in lung cancer PC-9 cells[J]. Natural Product Research and Development, 2017, 29(12): 2030-2035. | |
20 | CHEN K, LI A L, WANG J, et al. Arenobufagin causes ferroptosis in human gastric cancer cells by increasing rev-erbα expression[J]. J Tradit Complement Med, 2023, 13(1): 72-80. |
21 | WANG T J, MU L, JIN H F, et al. The effects of bufadienolides on HER2 overexpressing breast cancer cells[J]. Tumour Biol, 2016, 37(6): 7155-7163. |
22 | DELEBINSKI C I, GEORGI S, KLEINSIMON S, et al. Analysis of proliferation and apoptotic induction by 20 steroid glycosides in 143B osteosarcoma cells in vitro[J]. Cell Prolif, 2015, 48(5): 600-610. |
23 | DENG L J, PENG Q L, WANG L H, et al. Arenobufagin intercalates with DNA leading to G2 cell cycle arrest via ATM/ATR pathway[J]. Oncotarget, 2015, 6(33): 34258-34275. |
24 | ZHAO J M, ZHANG Q S, ZOU G Y, et al. Arenobufagin, isolated from toad venom, inhibited epithelial-to-mesenchymal transition and suppressed migration and invasion of lung cancer cells via targeting IKKβ/NFκB signal cascade[J]. J Ethnopharmacol, 2020, 250: 112492. |
25 | SRINIVAS N R. Arenobufagin: a potential novel opportunity for prostate cancer treatment - Intriguing mechanistic data but some questions on in vivo translatability[J]. Pharmacol Res, 2018, 128: 400-401. |
26 | CHEN L P, MAI W Q, CHEN M F, et al. Arenobufagin inhibits prostate cancer epithelial-mesenchymal transition and metastasis by down-regulating β-catenin[J]. Pharmacol Res, 2017, 123: 130-142. |
27 | GONG M M, WANG X, MU L, et al. Steroid receptor coactivator-1 enhances the stemness of glioblastoma by activating long noncoding RNA XIST/miR-152/KLF4 pathway[J]. Cancer Sci, 2021, 112(2): 604-618. |
28 | FOLKMAN J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182-1186. |
29 | 刘俊珊, 张冬梅, 陈敏锋, 等. 沙蟾毒精抑制血管生成的作用[J]. 药学学报, 2011, 46(5): 527-533. |
LIU J S, ZHANG D M, CHEN M F, et al. Anti-angiogenetic effect of arenobufagin in vitro and in vivo[J]. Acta Pharmaceutica Sinica, 2011, 46(5): 527-533. | |
30 | YUAN B, LI J M, MIYASHITA S I, et al. Enhanced cytotoxic effects of arenite in combination with active bufadienolide compounds against human glioblastoma cell line U-87[J]. Molecules, 2022, 27(19): 6577. |
31 | LIU C W, LI D C, WANG J, et al. Arenobufagin increases the sensitivity of gastric cancer to cisplatin via alkaliptosis[J]. Heliyon, 2023, 9(11): e21110. |
32 | YUE Q X, ZHEN H, HUANG M, et al. Proteasome inhibition contributed to the cytotoxicity of arenobufagin after its binding with Na, K-ATPase in human cervical carcinoma HeLa cells[J]. PLoS One, 2016, 11(7): e0159034. |
33 | DENG L J, WANG L H, PENG C K, et al. Fibroblast activation protein α activated tripeptide bufadienolide antitumor prodrug with reduced cardiotoxicity[J]. J Med Chem, 2017, 60(13): 5320-5333. |
34 | YUAN X, XIE Q, SU K Y, et al. Systemic delivery of the anticancer agent arenobufagin using polymeric nanomicelles[J]. Int J Nanomedicine, 2017, 12: 4981-4989. |
35 | YANG J Y, SUN B, WEI X L, et al. Arenobufagin-loaded PEG-PLA nanoparticles for reducing toxicity and enhancing cancer therapy[J]. Drug Deliv, 2023, 30(1): 2177362. |
[1] | HAN Yongqi, HAN Da, XIA Qian, JI Dingkun, TAN Weihong. Aptamer-drug conjugates (ApDCs): new trend for cancer precision therapy [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(9): 1176-1181. |
[2] | ZHU Nan, LIU Bingya, YU Beiqin. Advances in the role of muscle blind-like protein 1 in malignant tumors [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(10): 1474-1481. |
[3] | LI Ying-ying1, LUO Ya-ping2, FU Guo-hui1, 2, CHEN Shi-hui1. Inhibition of gastrin on catabolism of rat chondrocytes inducedinterleukin-1β [J]. , 2019, 39(8): 861-. |
[4] | ZHAO Qian-qian, HAN Hong-xiu. Research advances of the involvement of cannabinoid receptor 1 in the nerve growth [J]. , 2015, 35(8): 1225-. |
[5] | WU Shi-yu, LI Miao-zhu, LIU Yan, et al. Meta-analysis of correlation between tea consumption and risk of ovarian cancer [J]. , 2011, 31(6): 840-. |
[6] | YANG Zhi, NING Guang. Relationship between nonalcoholic fatty liver disease and obesity [J]. , 2011, 31(11): 1652-. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||